Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K   CURRENT REPORT   Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934   Date of report (Date of earliest event reported): May 24, 2018 (May 22, 2018)   Merck & Co., Inc. (Exact name of registrant as specified in its charter)             New Jersey   1-6571   22-1918501 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)     2000 Galloping Hill Road, Kenilworth, NJ   07033 (Address of principal executive offices)   (Zip code)   Registrant’s telephone number, including area code:  (908) 740-4000   Not Applicable   (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 5.07. Submission of Matters to a Vote of Security Holders. (a) The Annual Meeting of Shareholders of Merck & Co., Inc. (the "Company") was held on May 22, 2018. (b) Shareholders voted on the matters set forth below: Item 1 . All of the following persons nominated were elected to serve as directors and received the number of votes set forth opposite their respective names:   Names   Votes For   Votes Against   Abstentions   Broker Non-Votes Leslie A. Brun   1,827,098,962   102,392,479   17,434,638   377,689,096 Thomas R. Cech, Ph.D.   1,933,013,873   10,078,270   3,833,936   377,689,096 Pamela J. Craig   1,923,215,576   20,040,572   3,669,931   377,689,096 Kenneth C. Frazier   1,868,544,596   72,397,245   5,984,238   377,689,096 Thomas H. Glocer   1,903,562,070   39,186,407   4,177,602   377,689,096 Rochelle B. Lazarus   1,907,501,758   35,633,410   3,790,911   377,689,096 John H. Noseworthy, M.D.   1,935,362,697   7,617,284   3,946,098   377,689,096 Paul B. Rothman, M.D.   1,935,440,135   7,527,286   3,958,658   377,689,096 Patricia F. Russo   1,855,506,892   87,686,345   3,732,842   377,689,096 Craig B. Thompson, M.D.   1,928,220,863   14,788,148   3,917,068   377,689,096 Inge G. Thulin   1,806,775,605   136,388,582   3,761,892   377,689,096 Wendell P. Weeks   1,670,043,646   272,857,131   4,025,302   377,689,096 Peter C. Wendell   1,921,321,065   21,606,797   3,998,217   377,689,096 Item 2 . A proposal to approve, by non-binding advisory vote, the compensation of our Named Executive Officers received the following votes: For   Against   Abstained   Broker Non-Votes   1,832,053,440   105,387,018   9,485,621   377,689,096   Item 3 . A proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2018 received the following votes: For   Against   Abstained     2,281,231,563   37,071,153   6,312,459     Item 4 .    A shareholder proposal concerning shareholders' right to act by written consent received the following votes: For   Against   Abstained   Broker Non-Votes   867,269,109   1,066,251,463   13,405,507   377,689,096   A majority of votes cast was required for all four proposals to be approved. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 24, 2018                       Merck & Co., Inc.                 By:   /s/ Faye C. Brown             Name: Faye C. Brown Title: Senior Assistant Secretary